Literature DB >> 31285578

Trials and therapies in secondary progressive MS, simplified.

Navid Manouchehri1, Olaf Stüve2,3.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31285578     DOI： 10.1038/s41582-019-0233-x

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  3 in total

1.  The Efficacy and Safety of Anti-CD20 Antibody Treatments in Relapsing Multiple Sclerosis: A Systematic Review and Network Meta-analysis.

Authors:  Xin Wu; Xin Tan; Jie Zhang; Zilan Wang; Wenxue Wu; Shixin Wang; Yanfei Liu; Zhong Wang
Journal:  CNS Drugs       Date:  2022-10-16       Impact factor: 6.497

2.  Choroid plexus volumetrics and brain inflammation in multiple sclerosis.

Authors:  Navid Manouchehri; Olaf Stüve
Journal:  Proc Natl Acad Sci U S A       Date:  2021-10-05       Impact factor: 11.205

Review 3.  Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure.

Authors:  Navid Manouchehri; Victor H Salinas; Negar Rabi Yeganeh; David Pitt; Rehana Z Hussain; Olaf Stuve
Journal:  Front Neurol       Date:  2022-03-31       Impact factor: 4.003
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.